DVT Prophylaxis Heparin Dosing
For DVT prophylaxis in hospitalized adult patients, use unfractionated heparin 5,000 units subcutaneously every 8 hours, or alternatively enoxaparin 40 mg subcutaneously once daily or dalteparin 5,000 units subcutaneously once daily. 1, 2
Standard Prophylactic Dosing
Unfractionated Heparin (UFH)
- 5,000 units subcutaneously every 8 hours 1, 2, 3
- Note: 5,000 units every 12 hours has been used but appears less effective 1, 2
- Continue for duration of hospitalization or until fully ambulatory 1, 2
Low-Molecular-Weight Heparins (LMWH)
- Enoxaparin: 40 mg subcutaneously once daily 1, 2
- Dalteparin: 5,000 units subcutaneously once daily 1, 2
- Fondaparinux: 2.5 mg subcutaneously once daily (not FDA-approved for this indication) 1, 2
Duration
- Medical patients: Continue until hospital discharge or fully ambulatory 1, 2
- Surgical patients: Minimum 7-10 days; consider extended prophylaxis up to 4 weeks for high-risk patients 1, 2
Critical Adjustments for Renal Impairment
Severe Renal Impairment (CrCl <30 mL/min)
Switch to unfractionated heparin 5,000 units every 8-12 hours, as it does not require renal dose adjustment. 4
If LMWH must be used:
- Enoxaparin: Reduce to 30 mg subcutaneously once daily 4, 3
- Dalteparin: Can use 5,000 units once daily without dose adjustment for prophylaxis; monitor anti-Xa levels if concerned (target trough <0.40 IU/mL) 4, 5
- Fondaparinux: Contraindicated 4
- Tinzaparin: Avoid in patients ≥70 years with renal insufficiency due to increased mortality risk 4
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Use caution with LMWHs; consider dose reduction or switch to UFH 4
- Enoxaparin clearance reduced by 31% in this range 4
- Monitor for signs of accumulation if continuing LMWH
Key Evidence on Renal Impairment
Research demonstrates that prophylactic-dose dalteparin (5,000 units daily) does not bioaccumulate in critically ill patients with severe renal impairment (CrCl <30 mL/min), with peak anti-Xa levels of 0.29-0.34 IU/mL and no trough levels exceeding 0.40 IU/mL 5. However, enoxaparin at standard therapeutic doses shows 2-3 fold increased bleeding risk in severe renal impairment without dose adjustment 4.
Special Populations
Surgical Patients
- UFH: 5,000 units 2-4 hours preoperatively, then every 8 hours 1, 2, 3
- Enoxaparin: 40 mg 2-4 hours preoperatively or 10-12 hours preoperatively, then 40 mg once daily 1, 2
- Dalteparin: 2,500 units 2-4 hours preoperatively and 5,000 units once daily thereafter, OR 5,000 units 10-12 hours preoperatively and 5,000 units once daily thereafter 1, 2
Obese Patients (BMI >40 kg/m²)
- Consider higher doses or twice-daily dosing
- Standard dalteparin 5,000 units daily may be ineffective 4
- For heart failure patients: enoxaparin 60 mg once daily achieved appropriate prophylaxis without increased bleeding 6
Low Body Weight (<50 kg)
- Use caution with standard doses 4
- Consider reduced-dose prophylaxis (enoxaparin 30 mg daily or heparin 5000 units every 12 hours), which showed lower bleeding rates without increased VTE 7
- Fondaparinux: use with caution 4
Elderly (>70 years)
Cancer Patients
- Same dosing as general population for prophylaxis 1, 2
- LMWHs preferred over UFH for treatment of established VTE 1, 2
Common Pitfalls
Using UFH every 12 hours instead of every 8 hours: The every-12-hour regimen is less effective 1, 2
Failing to adjust for renal function: Always calculate creatinine clearance before initiating LMWH prophylaxis 4
Continuing LMWH in deteriorating renal function: Reassess renal function regularly in critically ill patients 4
Not monitoring platelets: Check platelet count every 2-3 days from day 4-14 when using UFH to screen for heparin-induced thrombocytopenia 8, 3
Assuming all LMWHs are equivalent in renal impairment: They have different pharmacokinetic profiles; enoxaparin has the most data supporting dose adjustment 4